Edition:
United Kingdom

Tetraphase Pharmaceuticals Inc (TTPH.OQ)

TTPH.OQ on NASDAQ Stock Exchange Global Select Market

5.78USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$5.78
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
227,937
52-wk High
$9.69
52-wk Low
$3.59

Latest Key Developments (Source: Significant Developments)

Tetraphase Pharmaceuticals Q3 loss per share $0.63
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Tetraphase Pharmaceuticals Inc :Tetraphase pharmaceuticals reports third quarter 2017 financial results and highlights recent clinical and corporate achievements.Q3 loss per share $0.63.Q3 revenue $4.1 million versus $900,000.Q3 revenue view $1.3 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.69 -- Thomson Reuters I/B/E/S.  Full Article

Tetraphase Pharmaceuticals signs commercial supply agreement with Finorga
Friday, 20 Oct 2017 

Oct 20 (Reuters) - Tetraphase Pharmaceuticals Inc ::Tetraphase Pharmaceuticals Inc says ‍on October 16 co and finorga sas entered into a commercial supply agreement​ - sec filing.Tetraphase Pharmaceuticals - ‍under supply agreement finorga sas will make for commercial supply active pharmaceutical ingredient for eravacycline for co​.Tetraphase Pharmaceuticals- ‍supply agreement has initial term ending Oct 16, 2022.  Full Article

TETRAPHASE PHARMACEUTICALS APPOINTS KAM UNNINAYAR AS CFO
Monday, 16 Oct 2017 

Oct 16 (Reuters) - Tetraphase Pharmaceuticals Inc ::TETRAPHASE PHARMACEUTICALS APPOINTS KAM UNNINAYAR AS CHIEF FINANCIAL OFFICER.‍MOST RECENTLY, KAMALAM UNNINAYAR​ SPENT OVER 11 YEARS OVERSEEING FINANCE ORGANIZATIONS AT THERMO FISHER SCIENTIFIC.KAMALAM UNNINAYAR MOST RECENTLY SPENT OVER 11 YEARS OVERSEEING FINANCE ORGANIZATIONS AT THERMO FISHER SCIENTIFIC​.  Full Article

Tetraphase pharmaceuticals doses first patient in IGNITE4 phase 3 clinical trial of Eravacycline in cIAI
Friday, 14 Oct 2016 

Tetraphase Pharmaceuticals Inc : Tetraphase Pharmaceuticals doses first patient in IGNITE4 phase 3 clinical trial of eravacycline in cIAI . Tetraphase Pharmaceuticals Inc - top-line IGNITE4 data expected in 4Q 2017 .Tetraphase Pharmaceuticals Inc- study is expected to enroll approximately 450 adult patients.  Full Article

Tetraphase Pharmaceuticals reports Q2 loss per share $0.47
Thursday, 4 Aug 2016 

Tetraphase Pharmaceuticals Inc : Q2 loss per share $0.47 . Q2 revenue view $2.1 million -- Thomson Reuters I/B/E/S . Tetraphase pharmaceuticals reports second quarter 2016 financial results and highlights recent progress . Q2 revenue $1.2 million versus $3.3 million . Q2 earnings per share view $-0.46 -- Thomson Reuters I/B/E/S .Cash, cash equivalents, expected revenue from u.s. Government awards, will be sufficient to fund operations into middle of 2018.  Full Article

BRIEF-Tetraphase Pharmaceuticals Q3 loss per share $0.63

* Tetraphase pharmaceuticals reports third quarter 2017 financial results and highlights recent clinical and corporate achievements